Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Eli Lilly announced that the highest doses of tirzepatide (Zepbound) -- 12.5 mg and 15 mg -- will soon be available in single ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly shares have soared in value in recent years due to the success of its GLP-1 drugs. Viking Therapeutics and ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...